Th response to Helicobacter pylori differs between patients with gastric ulcer and duodenal ulcer
Th response to Helicobacter pylori differs between patients with gastric ulcer and duodenal ulcer
复制标题
DOI：
10.1080/00365520510015520
复制
发表时间：
2005-06-01
影响因子：
1.9
通讯作者：
Wakatsuki, Y
中科院分区：
文献类型：
--
作者：
Itoh, T;Seno, H;Wakatsuki, Y
目标。幽门螺杆菌感染可引起胃（GU）和十二指肠溃疡（DU）。我们研究了宿主对幽门螺杆菌的免疫反应是否决定了不同的疾病结局。材料和方法。入选幽门螺杆菌感染的GU患者32例，DU患者28例，未感染的消化不良患者24例。每位患者的活组织检查中浸润细胞的成分被确定，受刺激的T细胞分泌的淋巴因子被测量。测定血清中幽门螺杆菌特异性IgG亚类的浓度。结果。GU患者胃蛋白酶原I水平低、II水平高，DU患者胃蛋白酶原I水平高。在GU和DU患者中，T细胞比其他细胞类型占优势。GU患者T细胞数量高于DU患者（p< 0.01），浆细胞数量低于DU患者（p< 0.05）。GU患者的T细胞比DU患者产生更多的ifn - γ和更少的IL-4 （p< 0.01）。GU患者血清幽门螺杆菌特异性IgG2水平高于DU患者（p< 0.01）。结论。与DU患者相比，GU患者胃T细胞对Th1的反应更极化，表明对幽门螺杆菌的不同免疫反应导致了不同的疾病结局。
Objective. Helicobacter pylori ( H. pylori) infection induces both gastric (GU) and duodenal ulcers (DU). We examined whether host immunological response to H. pylori determines different disease outcomes. Material and methods. Thirty-two GU and 28 DU patients infected with H. pylori, and 24 dyspeptic patients without infection were enrolled. The constituents of cellular infiltrates in biopsies from each patient were determined and lymphokines secreted by stimulated T cells were measured. Serum concentrations of IgG subclasses specific to H. pylori were measured. Results. Low pepsinogen I and high pepsinogen II levels were observed in GU patients, while a high pepsinogen I level was found in DU patients. T cells predominate over other cell types in both GU and DU patients. GU patients had a higher number of T cells ( p< 0.01) and lower plasma cells ( p< 0.05) than those in DU patients. T cells from GU patients produced greater amounts of IFN-gamma and less IL-4 than those in DU patients ( p< 0.01). GU patients had a higher serum level of IgG2 specific to H. pylori than that in DU patients ( p< 0.01). Conclusions. Th response by gastric T cells in GU patient was more polarized to Th1 as compared with that in DU patients, suggesting that a distinct immune response to H. pylori induces different disease outcomes.